Navigation Links
Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs

BOULDER, Colo.--(BUSINESS WIRE)--Jun 20, 2007 - Array BioPharma Inc. (Nasdaq: ARRY) announced new Phase 1 clinical data on its MEK inhibitor, ARRY-162, and its p38 inhibitor, ARRY-797. These results were presented at the Annual European Congress of Rheumatology (EULAR) in Barcelona, Spain, and at the International Association of Inflammation Societies' (IAIS) 8th World Congress on Inflammation in Copenhagen, Denmark.

ARRY-162 / MEK Inhibitor Phase 1 Results

Array presented preliminary information on its MEK inhibitor, ARRY-162, from both a single ascending dose (SAD) and a multiple ascending dose (MAD) Phase 1 clinical trial. In the SAD study, the drug was given orally at doses of 5 to 80 mg. In blood samples taken from these volunteers and stimulated ex vivo, ARRY-162 was shown to inhibit the production of IL-1beta, TNF-alpha, IL-6 and phosphoERK (pERK). IL-1beta was inhibited most potently and to the greatest extent, whereas pERK, a measure of proliferation, was the least inhibited. In the MAD study, volunteers were given doses ranging from 5 to 60 mg daily, for 14 days. Steady state drug exposure was proportional to dose and did not change with repeated dosing. In volunteers receiving daily doses of 40 mg of ARRY-162, inhibition of 50 to 90 percent of IL-1beta, TNF-alpha, and IL-6 was observed when measured over a 24-hour period. There were no significant changes in clinical laboratory values and no serious adverse events observed in either the SAD or MAD studies. Dose escalation studies with ARRY-162, in combination with methotrexate, are ongoing in rheumatoid arthritis patients with stable disease. Phase 2 studies are planned to start by the end of 2007.

ARRY-797 / p38 Inhibitor Phase 1 Results

In a SAD study in healthy volunteers, ARRY-797 was shown to have linear increases in exposure with increasing oral dose; the dose range studied was from 25 to 400 mg. The drug was well-tolerated
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
Post Your Comments:
(Date:5/23/2013)...  BioElectronics Corporation (OTC Pink: BIEL), the maker of ... FDA panel meeting for non-thermal shortwave diathermy: ... Therapy Meeting was held on May 21, 2013 in ... of the meeting was very narrow, in that the ... the application of non-thermal shortwave diathermy for the treatment ...
(Date:5/23/2013)... , May 23, 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ... company focused on the development and commercialization of novel ... as primary biliary cirrhosis, today announced that ... Officer, will present at the Deutsche Bank Securities 38th ... on Wednesday, May 29, 2013 at 4:10 p.m. ...
(Date:5/23/2013)... , May 23, 2013  Inhibikase Therapeutics, Inc., ... today that it will present new results on ... industry conference sponsored by the PML Consortium (composed ... JC polyomavirus (JCV) is the causative agent of ... kinase inhibitor in an extended release formulation, can ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2
... , June 2 At a time when employers are ... Inc. has revealed that the integration of medical and pharmacy benefits lowers ... , , ... costs, some employers choose a "carve-out" model by contracting with a pharmacy ...
... CARTERSVILLE, Ga. ; June 2 ... (GASC) – Georgia ,s first fully accredited ... gynecological surgeries in a true outpatient ... specializes in laparoscopic and other highly advanced, minimally ...
Cached Medicine Technology:Highmark Study Shows Integrated Medical and Pharmacy Benefits Lower Costs, Promote Better Health 2Highmark Study Shows Integrated Medical and Pharmacy Benefits Lower Costs, Promote Better Health 3New Georgia Advanced Surgery Center Provides Women Many Unique Benefits 2
(Date:5/23/2013)... 2013 Memorial Day is Monday, May 27, ... for many Americans. Across the nation, people will have picnics, ... Americans to reach out to those who have experienced the ... the nation marks Memorial Day this year, the U.S. is ... deaths of brave service men and women remind all Americans ...
(Date:5/23/2013)... 23, 2013 A medical malpractice case ... (reference number 110504/2009) by Lori Mandel, an office manager ... Mandel $8.6 million. Ms. Mandel sought the medical expertise ... to further complications that affected the quality of her ... The plaintiff alleged that her doctor rendered conservative treatment ...
(Date:5/23/2013)... - New techniques in imaging of brain activity ... Montreal Neurological Institute, and his colleagues lead to ... The combination of electroencephalogram (EEG) and functional magnetic ... of the areas generating epileptic seizures, giving neurosurgeons ... intervention, if appropriate. These results were presented ...
(Date:5/23/2013)... May 23, 2013 According to a ... Services; Policy Management; Subscriber Data Management (SDM); Telecom Application ... and Analysis (2013 – 2018)", published by MarketsandMarkets, the ... 2018 at a CAGR of 9.15% from 2013 to ... Data Tables , 84 Figures , ...
(Date:5/23/2013)... In Florida, residents have not been hit with a ... Florida’s good luck will continue, warns Rick Knabb, Director of ... residents, it is important to prepare as if one could ... to be a 50-percent chance that a major hurricane could ... from June 1 to November 30 in Florida, this makes ...
Breaking Medicine News(10 mins):Health News:Memorial Day: Make it a Time of Remembrance and Support 2Health News:Memorial Day: Make it a Time of Remembrance and Support 3Health News:New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury 2Health News:New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury 3Health News:New imaging techniques used to help patients suffering from epilepsy 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 3Health News:As Hurricane Season Nears, Skylake Insurance Encourages Florida Residents To Prepare Early For Safety 2
... President & Chief Executive Officer of Concurrent Technologies Corporation ( ... awarded a contract with a potential value of $90,000 and ... announcement to kick off Johnstown,s Annual Showcase for Commerce. ... for Disease Control and Prevention (CDC) with Information Technology (IT) ...
... daily consensus interferon (CIFN) and ribavirin is effective for some ... to standard therapy. The treatment works particularly well in interferon-sensitive ... study in the June issue of Hepatology , a ... the American Association for the Study of Liver Diseases (AASLD). ...
... 28 "Financially distressed employees have trouble functioning ... physical health as well as taking a bite ... E. Thomas Garman, president, Personal Finance Employee Education ... health. One-third of school, hospital, and technology employees ...
... 28 StemCyte, Inc., a privately held cord ... released their 1,000th cord blood stem cell shipment ... company,s rapid growth as one of the world,s ... cell product.(Photo: http://www.newscom.com/cgi-bin/prnh/20090528/NY23885LOGO ...
... A new statewide poll of registered voters ... bill to give the U.S. Food and Drug Administration (FDA) ... is expected to debate this issue next week, and Senators ... whether Congress will finally pass this life-saving legislation.(Logo: ...
... Calif., May 27, 2009 Amgen (NASDAQ: AMGN) ... Interactive, Inc. survey indicating that the vast majority ... highly concerned about the negative impact infection may ... well as emerging antibiotic resistance. Nearly all oncologists ...
Cached Medicine News:Health News:Concurrent Technologies Corporation Awarded Contract to Support the Centers for Disease Control and Prevention with Readiness Efforts 2Health News:New treatment option for patients with chronic hepatitis C 2Health News:Financial Distress Taking Toll on Employee Health 2Health News:StemCyte, Inc. Reaches 1,000th Cord Blood Stem Cell Shipment for Transplant Milestone 2Health News:New Virginia Poll: 71 Percent of Voters Strongly Support FDA Regulation of Tobacco Products 2Health News:New Virginia Poll: 71 Percent of Voters Strongly Support FDA Regulation of Tobacco Products 3Health News:New survey highlights growing concern about risk of infection in cancer patients 2Health News:New survey highlights growing concern about risk of infection in cancer patients 3Health News:New survey highlights growing concern about risk of infection in cancer patients 4Health News:New survey highlights growing concern about risk of infection in cancer patients 5
At 14 cm point, ruler is bent at 90 degrees angle brought to a blunt point at 15 cm....
Colorado Microneedles offer the surgeon precision in cutting and coagulation, without the expense and inconvenience of a laser. The needles may also be used for dissecting large areas such as the sca...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: